Synthesis, antimicrobial potency with in silico study of Boc-leucine-1,2,3-triazoles

A library of N-Boc protected Leucine-linked 1,4-disubstituted 1,2,3-triazoles was synthesized and fully characterized, in high yield via copper-catalyzed alkyne-azide cycloaddition (CuAAC) reaction. In vitro antibacterial activity showed that compound 4h found to be more potent than the reference drug Ciprofloxacin (MIC: 0.0196 µmol/mL) against tested bacterial strains S. entrica, B. subtilis, S. aureus, E. coli and P. auroginosa with MIC: 0.0148, 0.0074, 0.0148, 0.0074, and 0.0074 µmol/mL, respectively and antifungal activity with MIC: 0.0148 µmol/mL as compared to reference drug Fluconazole (MIC: 0.0102 µmol/mL) against A. niger and C. albicans fungal strains. Further, the molecular docking study on 4h and its predecessor alkyne 3 by choosing E. coli topoisomerase II, DNA Gyrase (PDB ID: 1KZN) showed better binding with triazole than alkyne and these results were supported by DFT study using B3LYP/6-311G(d,p) basis set. [Display omitted] •New library of N-Boc-Leucine-1,2,3-triazoles was synthesized in high yield.•All synthesized compounds were characterized by FTIR, 1H &13C NMR, and MS data.•Compound 4h found better than reference drug Ciprofloxacin for all tested bacterial strains.•Compound 4h exhibited comparable antifungal activity to reference drug Fluconazole.•Molecular docking on DNA Gyrase (PDB ID: 1KZN) exhibited better binding with triazole 4h than alkyne 3.•Antimicrobial and Molecular docking results were supported by DFT study. A library of N-Boc protected Leucine-linked 1,4-disubstituted 1,2,3-triazoles was synthesized and fully characterized, in high yield via copper-catalyzed alkyne-azide cycloaddition (CuAAC) reaction. In vitro antibacterial activity showed that compound 4h found to be more potent than the reference drug Ciprofloxacin (MIC: 0.0196 µmol/mL) against tested bacterial strains S. entrica, B. subtilis, S. aureus, E. coli and P. auroginosa with MIC: 0.0148, 0.0074, 0.0148, 0.0074, and 0.0074 µmol/mL, respectively and antifungal activity with MIC: 0.0148 µmol/mL as compared to reference drug Fluconazole (MIC: 0.0102 µmol/mL) against A. niger and C. albicans fungal strains. Further, the molecular docking study on 4h and its predecessor alkyne 3 by choosing E. coli topoisomerase II, DNA Gyrase (PDB ID: 1KZN) showed better binding with triazole than alkyne and these results were supported by DFT study using B3LYP/6-311G(d,p) basis set.